Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Janice Dutcher

New York, NY Medical Doctor

NPI 1730242124 CMS profile 124201

1000 10Th Ave, 11Th Floor, New York, NY 10019

Open in the dashboard

General payments

$762,938

160 records reported · program years 2019–2025

Research payments

$140,054

Paid to them · 50 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Janice Dutcher of New York, NY is reported in the CMS Open Payments database as having received $762,938 across 160 general payments and $140,054 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $155,412 14
2025 Research $48,127 26
2024 General $125,339 12
2024 Research $69,216 19
2023 General $58,531 10
2023 Research $15,502 3
2022 General $74,228 20
2022 Research $7,210 2
2021 General $108,055 31
2020 General $139,771 42
2019 General $101,602 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Janice Dutcher
  • New York median
  • Middle half of New York
  • National median

In program year 2025, general payments to Janice Dutcher were reported at $155,412. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.

Show as a table
Year Janice Dutcher New York median Middle half National median
2019 $101,602 $175 $53–$665 $163
2020 $139,771 $122 $37–$426 $114
2021 $108,055 $144 $44–$514 $132
2022 $74,228 $160 $51–$578 $149
2023 $58,531 $170 $54–$593 $160
2024 $125,339 $173 $56–$618 $164
2025 $155,412 $180 $58–$640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Daiichi Sankyo Inc. $260,625 18 payments
  2. E.R. Squibb & Sons, L.L.C. $205,823 52 payments
  3. Merck Sharp & Dohme Corporation $173,958 52 payments
  4. Eisai Inc. $94,513 22 payments
  5. Amgen Inc. $16,538 9 payments
  6. Iovance Biotherapeutics, Inc. $7,875 3 payments
  7. AstraZeneca Pharmaceuticals LP $3,000 1 payment
  8. Clinigen Inc $480 1 payment
  9. Celgene Corporation $96 1 payment
  10. BeOne Medicines USA, Inc. $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $762,328 157 payments
  2. Travel and Lodging $482 1 payment
  3. Food and Beverage $127 2 payments
Products named General payments · program years 2019–2025
  1. ENHERTU $260,625 18 payments
  2. LENVIMA Oncology $100,000 32 payments
  3. Lenvima Oncology $94,513 22 payments
  4. OPDIVO $72,225 18 payments
  5. KEYTRUDA $45,745 14 payments
  6. IMLYGIC $16,538 9 payments
  7. Amtagvi $7,875 3 payments
  8. Proleukin $480 1 payment
  9. BRUKINSA $31 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $140,054 50 payments

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record